A study of more than 333,000 US veterans with type 2 diabetes finds the heart-protective benefits of Ozempic, Wegovy, Mounjaro and Zepbound erode within as little as six months of stopping, and are not fully restored by resuming treatment.
A study of more than 333,000 US veterans with type 2 diabetes finds the heart-protective benefits of Ozempic, Wegovy, Mounjaro and Zepbound erode within as little as six months of stopping, and are not fully restored by resuming treatment.